Cargando…

Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer

BACKGROUND: The Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) groups has identified four molecular prognostic groups of endometrial cancer (EC): POLE-mutated (POLE-mt), mismatch repair-deficient (MMR-d), p53-abnormal (p53-abn), p53-wild-type (p53-wt). These groups might have d...

Descripción completa

Detalles Bibliográficos
Autores principales: Raffone, Antonio, Travaglino, Antonio, Gabrielli, Olimpia, Micheli, Mariacarolina, Zuccalà, Valeria, Bitonti, Giovanna, Camastra, Caterina, Gargiulo, Valentina, Insabato, Luigi, Zullo, Fulvio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087601/
https://www.ncbi.nlm.nih.gov/pubmed/33754186
http://dx.doi.org/10.1007/s00404-021-06028-4
_version_ 1783686698148823040
author Raffone, Antonio
Travaglino, Antonio
Gabrielli, Olimpia
Micheli, Mariacarolina
Zuccalà, Valeria
Bitonti, Giovanna
Camastra, Caterina
Gargiulo, Valentina
Insabato, Luigi
Zullo, Fulvio
author_facet Raffone, Antonio
Travaglino, Antonio
Gabrielli, Olimpia
Micheli, Mariacarolina
Zuccalà, Valeria
Bitonti, Giovanna
Camastra, Caterina
Gargiulo, Valentina
Insabato, Luigi
Zullo, Fulvio
author_sort Raffone, Antonio
collection PubMed
description BACKGROUND: The Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) groups has identified four molecular prognostic groups of endometrial cancer (EC): POLE-mutated (POLE-mt), mismatch repair-deficient (MMR-d), p53-abnormal (p53-abn), p53-wild-type (p53-wt). These groups might have different pathogenesis and risk factors, and might occur in different phenotypes of patients. However, these data are still lacking. OBJECTIVE: To provide a clinical characterization of the ProMisE groups of EC. METHODS: A systematic review and meta-analysis was performed by searching seven electronic databases from their inception to December 2020, for all studies reporting clinical characteristics of EC patients in each ProMisE group. Pooled means of age and BMI and pooled prevalence of FIGO stage I and adjuvant treatment in each ProMisE group were calculated. RESULTS: Six studies with 1, 879 women were included in the systematic review. Pooled means (with standard error) and prevalence values were: in the MMR-d group, age = 66.5 ± 0.6; BMI = 30.6 ± 1.2; stage I = 72.6%; adjuvant treatment = 47.3%; in the POLE-mt group, age = 58.6 ± 2.7; BMI = 27.2 ± 0.9; stage I = 93.7%; adjuvant treatment = 53.6%; in the p53-wt group, age = 64.2 ± 1.9; BMI = 32.3 ± 1.4; stage I = 80.5%; adjuvant treatment = 45.3%; in the p53-abn group, age = 71.1 ± 0.5; BMI = 29.1 ± 0.5; stage I = 50.8%; adjuvant treatment = 64.4%. CONCLUSION: The ProMisE groups identify different phenotypes of patients. The POLE-mt group included the youngest women, with the lower BMI and the highest prevalence of stage I. The p53-wt group included patients with the highest BMI. The p53-abn group included the oldest women, with the highest prevalence of adjuvant treatment and the lowest prevalence of stage I. The MMR-d group showed intermediate values among the ProMisE groups for all clinical features. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00404-021-06028-4.
format Online
Article
Text
id pubmed-8087601
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-80876012021-05-05 Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer Raffone, Antonio Travaglino, Antonio Gabrielli, Olimpia Micheli, Mariacarolina Zuccalà, Valeria Bitonti, Giovanna Camastra, Caterina Gargiulo, Valentina Insabato, Luigi Zullo, Fulvio Arch Gynecol Obstet Review BACKGROUND: The Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) groups has identified four molecular prognostic groups of endometrial cancer (EC): POLE-mutated (POLE-mt), mismatch repair-deficient (MMR-d), p53-abnormal (p53-abn), p53-wild-type (p53-wt). These groups might have different pathogenesis and risk factors, and might occur in different phenotypes of patients. However, these data are still lacking. OBJECTIVE: To provide a clinical characterization of the ProMisE groups of EC. METHODS: A systematic review and meta-analysis was performed by searching seven electronic databases from their inception to December 2020, for all studies reporting clinical characteristics of EC patients in each ProMisE group. Pooled means of age and BMI and pooled prevalence of FIGO stage I and adjuvant treatment in each ProMisE group were calculated. RESULTS: Six studies with 1, 879 women were included in the systematic review. Pooled means (with standard error) and prevalence values were: in the MMR-d group, age = 66.5 ± 0.6; BMI = 30.6 ± 1.2; stage I = 72.6%; adjuvant treatment = 47.3%; in the POLE-mt group, age = 58.6 ± 2.7; BMI = 27.2 ± 0.9; stage I = 93.7%; adjuvant treatment = 53.6%; in the p53-wt group, age = 64.2 ± 1.9; BMI = 32.3 ± 1.4; stage I = 80.5%; adjuvant treatment = 45.3%; in the p53-abn group, age = 71.1 ± 0.5; BMI = 29.1 ± 0.5; stage I = 50.8%; adjuvant treatment = 64.4%. CONCLUSION: The ProMisE groups identify different phenotypes of patients. The POLE-mt group included the youngest women, with the lower BMI and the highest prevalence of stage I. The p53-wt group included patients with the highest BMI. The p53-abn group included the oldest women, with the highest prevalence of adjuvant treatment and the lowest prevalence of stage I. The MMR-d group showed intermediate values among the ProMisE groups for all clinical features. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00404-021-06028-4. Springer Berlin Heidelberg 2021-03-23 2021 /pmc/articles/PMC8087601/ /pubmed/33754186 http://dx.doi.org/10.1007/s00404-021-06028-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review
Raffone, Antonio
Travaglino, Antonio
Gabrielli, Olimpia
Micheli, Mariacarolina
Zuccalà, Valeria
Bitonti, Giovanna
Camastra, Caterina
Gargiulo, Valentina
Insabato, Luigi
Zullo, Fulvio
Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer
title Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer
title_full Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer
title_fullStr Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer
title_full_unstemmed Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer
title_short Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer
title_sort clinical features of promise groups identify different phenotypes of patients with endometrial cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087601/
https://www.ncbi.nlm.nih.gov/pubmed/33754186
http://dx.doi.org/10.1007/s00404-021-06028-4
work_keys_str_mv AT raffoneantonio clinicalfeaturesofpromisegroupsidentifydifferentphenotypesofpatientswithendometrialcancer
AT travaglinoantonio clinicalfeaturesofpromisegroupsidentifydifferentphenotypesofpatientswithendometrialcancer
AT gabrielliolimpia clinicalfeaturesofpromisegroupsidentifydifferentphenotypesofpatientswithendometrialcancer
AT michelimariacarolina clinicalfeaturesofpromisegroupsidentifydifferentphenotypesofpatientswithendometrialcancer
AT zuccalavaleria clinicalfeaturesofpromisegroupsidentifydifferentphenotypesofpatientswithendometrialcancer
AT bitontigiovanna clinicalfeaturesofpromisegroupsidentifydifferentphenotypesofpatientswithendometrialcancer
AT camastracaterina clinicalfeaturesofpromisegroupsidentifydifferentphenotypesofpatientswithendometrialcancer
AT gargiulovalentina clinicalfeaturesofpromisegroupsidentifydifferentphenotypesofpatientswithendometrialcancer
AT insabatoluigi clinicalfeaturesofpromisegroupsidentifydifferentphenotypesofpatientswithendometrialcancer
AT zullofulvio clinicalfeaturesofpromisegroupsidentifydifferentphenotypesofpatientswithendometrialcancer